Japan-based Takeda Pharmaceutical has persuaded the European Union Intellectual Property Office that an applied-for trademark would be confused with its own earlier-registered mark
The EU General Court dismissed Canada-based Endoceutics’ trademark appeal in a win for medical technology company Merck KGaA on Thursday, November 22.
Denmark-based Leo Pharma and Californian rare disease company PellePharm have partnered to develop and commercialise therapies for rare forms of skin cancer.
The EU General Court has upheld a decision to deny Japanese medical device producer Asahi Intecc a trademark for a line of catheters it produces.
The strategies of generic makers in Russia have changed dramatically over the past few years, according to Natalia Gulyaeva, partner at Hogan Lovells.
The EU General Court handed a victory to Merck KGaA late last week, after rejecting a Swiss company’s trademark appeal.
While the pharmaceutical industry has welcomed the draft Withdrawal Agreement for the UK’s departure from the EU, more clarity is still needed, lawyers have told LSIPR.
Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.
Last year, for the first time in European Patent Office history, a Chinese company filed the most European patent applications, making an “impressive statement” on what companies in the country are doing, according to Peter Albrecht.
The speed of technological advancements in the life sciences industry is forcing patent lawyers to consider whether the norms they’re used to dealing with in the profession still apply.